Participated · Series C · Apr 2025

Glycomine is a clinical-stage biotech based in San Carlos, California, focused on developing transformative therapies for rare orphan diseases. Its lead candidate, GLM101, is a first-in-class mannose-1-phosphate replacement therapy designed to deliver mannose-1-phosphate into cells and bypass disease-causing PMM2 mutations to restore N-glycosylation. GLM101 has received Orphan Drug Designation in the U.S. and E.U., and Rare Pediatric Disease and Fast Track designations in the U.S. The company has enrolled more than 20 patients across Europe and the U.S. in an ongoing Phase 2 open-label study and has initiated dosing in pediatric patients. Data from the Phase 2 open-label study showed an average 11.9-point improvement on the ICARS among nine adult and adolescent patients over 24 weeks, providing clinical proof of concept for improvement in ataxia. Glycomine recently announced a $115 million Series C financing to support advancing GLM101 into a randomized, placebo-controlled Phase 2b safety and efficacy study later this year. Glycomine is a biotechnology company based in San Carlos, California, developing therapies for orphan diseases. Its lead candidate, GLM101, is a mannose-1-phosphate substrate replacement therapy designed to deliver mannose-1-phosphate intracellularly to bypass PMM2 enzyme deficiency and restore N-glycosylation. Preclinical studies have shown GLM101 can restore disrupted glycosylation pathways in PMM2-CDG. GLM101 has received Orphan Drug Designation in the U.S. and Europe and Rare Pediatric Disease Designation in the U.S. Glycomine plans to use the Series B proceeds to advance GLM101 into initial clinical trials and confirm clinical potential across PMM2-CDG genotypes. The company focuses on replacement therapies targeted to clinically relevant cellular compartments for rare metabolic and protein-misfolding disorders. Glycomine focuses on developing orphan drugs for serious rare monogenic disorders of metabolism and protein misfolding. The company’s approach combines replacement therapies—substrates, enzymes, or proteins—with delivery vehicles made of bio-nanomaterials or ligands to target molecules to the cell interior of relevant organs. Glycomine intends to use the new capital to advance its substrate replacement therapy for PMM2‑CDG (CDG‑1a) into early-stage clinical studies. The company raised $33m in a Series B financing led by Novo Holdings A/S. In connection with the financing, Peter McWilliams, Ph.D., moved from acting CEO to full-time CEO. Kenneth Harrison, Ph.D., of Novo Ventures and Chris Starr, Ph.D., joined the company’s board. Glycomine is a San Francisco, CA–based biotechnology company developing a new generation of replacement therapies for rare monogenic disorders of metabolism and protein misfolding. Its approach combines replacement therapies—substrates, enzymes, or proteins—with intracellular delivery vehicles consisting of bio‑nanomaterials or targeting ligands to deliver molecules into clinically relevant organs. The company is led by CEO Agnes Rafalko, PhD, with Christopher Starr, PhD serving as Executive Chairman. Glycomine raised $12m in a Series A financing to advance its pipeline. The company intends to use the funds to complete IND‑enabling preclinical studies and initiate clinical studies of a substrate replacement therapy in patients with Congenital Disorder of Glycosylation Type Ia (CDG‑Ia). Proceeds will also be used to accelerate discovery efforts toward an enzyme replacement therapy for N‑glycanase deficiency (Ngly1).

Participated · Series A · Jul 2024

Kins is a Boston-based digital-first hybrid physical therapy practice that combines virtual and in-person care to enable therapists and patients to collaborate on personalized care plans. The company operates a hybrid care platform for physical therapy delivery and coordination. Kins plans to use the Series A proceeds to accelerate development of its virtual and in-person care platform. The company also intends to expand into the Washington, D.C., Maryland, and Virginia markets. Led by CEO Dan Smith, Kins positions its model for collaboration with payers on value-based care delivery. The firm says it has proven its care model with patients, providers, and health systems. Kins operates a digital-first hybrid physical therapy model that combines in-home visits and virtual care to deliver patient-centric, 1-on-1 treatment. Founded in 2021 at Redesign Health and launched in New York in September 2021, Kins has expanded into Massachusetts and partners with payers and providers including Aetna, Cigna, UnitedHealthCare, Blue Cross Blue Shield, Harvard Pilgrim, and Optum Care. The company plans to use new financing to further develop its hybrid model and expand into additional markets while hiring and partnering in New York, Massachusetts, and other regions. Since launch, Kins reports 30% month-over-month growth, a 4.9 out of 5 patient satisfaction rating, 68% retention to care plan, and 71% clinical improvement per patient. Kins positions its approach as a solution to high clinic-centric dropout and therapist turnover by providing therapists autonomy, flexibility, and more time to build patient relationships.

Participated · Series A · Jun 2022

Swing Therapeutics develops daily-use prescription digital therapeutics for autoimmune and chronic overlapping pain conditions, with a focus on fibromyalgia. Its core products include a Digital Acceptance and Commitment Therapy (ACT) program and a Digital Symptom Tracker that combine lessons, interactive exercises, symptom monitoring, and health education. The company has received FDA Breakthrough Device Designation for its fibromyalgia digital therapy and is moving to validate that therapy in a pivotal Phase 3 trial (PROSPER-FM). Swing plans to use recent funding to support execution of PROSPER-FM and to launch an affiliated telemedicine clinic. Swing is also running the REACT-FM real-world evidence trial, with more than 100 people enrolled, and built PROSPER-FM on prior SMART-FM pilot results presented in 2021. The company aims to bring an FDA-cleared, prescription digital therapeutic to market to expand access to non-pharmacologic fibromyalgia treatments. Swing Therapeutics develops a self-guided, smartphone-based digital therapeutic that delivers acceptance and commitment therapy (ACT) adapted from a clinically validated University of Manitoba program. The core program is 12 weeks with a maintenance mode, includes lessons, interactive exercises and a flare‑triage tool, and is designed to improve function and symptoms in people with fibromyalgia. The company completed a pilot study that showed promise, has launched a real‑world study (REACT‑FM), and is planning a multicenter randomized pivotal trial to support FDA clearance. The FDA has granted the program Breakthrough Device Designation, and Swing is continuing clinical work to demonstrate safety and efficacy. Swing launched with $9 million in seed funding from JAZZ Venture Partners and is investing in research to validate its pipeline of prescription-based digital therapies. The company was founded in 2019 and is focused on bringing its fibromyalgia program to market as an FDA‑cleared, prescription digital therapeutic.

Participated · Series B · Feb 2022

Koya Medical is a transformative healthcare company focused on developing breakthrough treatments for venous diseases and lymphedema and providing personalized care. Led by CEO Andy Doraiswamy, the company aims to address substantial unmet needs for patients with progressive, incurable lymphedema. An estimated 20 million Americans live with lymphedema, which can result from cancer, chronic venous disease, infection, and surgery and often requires lifelong management. Koya plans to use the newly raised capital to support strategic expansion and continued growth. The company raised up to $30M in financing in a round led by OrbiMed. Koya is based in Oakland, CA. Koya Medical is a healthcare company developing wearable active compression systems to treat lymphedema and venous disorders. Its lead product, the Dayspring system, is a low-profile, mobility-enabled active compression therapy cleared by the U.S. FDA to treat lymphedema and similar conditions in the upper and lower extremities. Dayspring includes a soft, breathable garment using Koya’s proprietary Flexframe technology, a rechargeable handheld controller, and a mobile app for therapy tracking and custom programming. The company plans to use new funding to accelerate expansion and commercialization of Dayspring and to continue platform development and clinical research to pursue additional indications. Koya positions its technology to enable movement and muscle use to promote healthy fluid flow and improve quality of life compared with traditional compression. The privately held company was founded in 2018 and emphasizes patient-centric design. Koya Medical develops the Dayspring prescription-only active wearable compression system for treating lymphedema and venous insufficiency. Dayspring is FDA-cleared and is described as the first digitally connected system designed to enable patient mobility during use. The company is based in Oakland, Calif., and was founded in 2018. Andy Doraiswamy, PhD, serves as President and CEO. Koya recently closed an $11M Series A financing led by Arboretum Ventures. Jan Garfinkle of Arboretum will join the board while Josh Baltzell will continue as Chairman.

Participated · Equity · May 2021

Aerobiotix produces medical-grade air disinfection systems, including its Illuvia® ultraviolet photolytic chamber product, designed to break pathogen DNA and reduce healthcare-acquired infections. Its devices combine ultraviolet light, HEPA filters, and proprietary filtration to remove bacteria, viruses, VOCs and other contaminants, and are designed to run continuously in occupied rooms. The company reports its solutions are already being used in over 170 healthcare locations and include integrated tracking to help facilities measure and manage air quality. Aerobiotix says its technology can be applied beyond healthcare to schools, high-density residential, and commercial office buildings. Management plans to expand market share and develop additional indoor air quality solutions to meet surging demand. Prominent investors in the company include Vivo Capital and Asahi Kasei Corporate Venture Capital. Aerobiotix, founded in 2013 and based in Miamisburg, Ohio, is a global medical company that develops hospital-based airborne infection control products. The company has FDA 510(k) cleared air decontamination devices, including the operating-room ILLUVIA system, which use mechanical and ultraviolet filtration to reduce bacterial and viral contamination including SARS-CoV-2. Its devices are supported by multiple peer-reviewed research studies and include real-time air quality monitoring and internet-of-medical-things connectivity. Aerobiotix products have been used to support thousands of procedures across multiple surgical specialties and are deployed in over 175 hospitals and multiple long-term care facilities. The company raised $25 million in growth equity financing led by Vivo Capital with participation from Asahi Kasei Ventures. The new funding will be used to accelerate sales, marketing, and new product development to expand commercial traction domestically and internationally.